Evidence map›Paper›PMID 41146317›Full record

ArticleEuropean journal of medical research2025

Cholestasis as a complication in Kawasaki disease: an atypical clinical presentation.

Jiaxiang Hong, Chenchen Liu, Xunmin Wang, Xing Rong, Rongzhou Wu, Maoping Chu

Abstract read
In one paragraph

Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jiaxiang Hong *Children's Heart Center, Institute of Cardiovascular Development and Translational Medicine, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Chenchen Liu *Children's Heart Center, Institute of Cardiovascular Development and Translational Medicine, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Xunmin Wang *Children's Heart Center, Institute of Cardiovascular Development and Translational Medicine, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Xing Rong *Children's Heart Center, Institute of Cardiovascular Development and Translational Medicine, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Rongzhou WuChildren's Heart Center, Institute of Cardiovascular Development and Translational Medicine, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Maoping ChuChildren's Heart Center, Institute of Cardiovascular Development and Translational Medicine, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China. chmping@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCholestasis is an uncommon complication in Kawasaki disease (KD) that impacts the digestive system. This study aimed to examine the clinical characteristics and associated risk factors of KD complicated by cholestasis.

methodsAmong the 3026 KD patients admitted to Yuying Children's Hospital, affiliated with Wenzhou Medical University, from January 1, 2008, to December 31, 2020, all 72 children with cholestasis were included in the study. We performed a comprehensive analysis of the clinical characteristics, prognosis, and potential risk factors associated with KD patients presenting with cholestasis.

resultsAll 72 patients (median age: 34.1 months; 52.8% male) met the diagnostic criteria for cholestatic hepatitis. The mean duration of hospitalization was 10 days. Clinically, the incidence of limb edema and cervical lymphadenitis was relatively low. Pre-treatment assessments of liver function revealed significantly elevated levels of alanine aminotransferase, aspartate aminotransferase, and γ-glutamyl transpeptidase, with median values of 227 U/L, 102 U/L, and 220 U/L, respectively. Abdominal ultrasonography indicated an increased incidence of cholecystitis (12.5%) and hepatosplenomegaly (32.9%), in the absence of gallstones. Additionally, patients demonstrated an increased likelihood of systemic involvement, including pancreatitis and aseptic pyuria, alongside significantly elevated inflammatory markers such as C-reactive protein (CRP), white blood cell count (WBC), and neutrophil levels. All patients received treatment with intravenous immunoglobulin (IVIG) and aspirin, leading to the normalization of liver function indicators within one week. In this study, 25.0% of the patients demonstrated resistance to IVIG therapy, with 2 cases experiencing acute pancreatitis and shock. Furthermore, 25 patients developed coronary artery lesions, which resolved over a 32-month follow-up period as assessed by cardiac ultrasound.

conclusionWhen KD is complicated by cholestasis, it impacts the liver and bile ducts, leading to liver damage, cholecystitis, and jaundice, while also intensifying systemic inflammatory responses and increasing the likelihood of additional systemic involvements. Despite these complications, the prognosis is generally favorable; however, there is an associated elevated risk of resistance to IVIG therapy.

Indexed as

CholestasisMucocutaneous Lymph Node SyndromeChildChild, PreschoolFemaleHumansInfantMalePrognosisRetrospective StudiesRisk Factors

Identifiers

PMID41146317
PMCPMC12560351

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.